Sobre el VHIR
Al Vall d’Hebron Institut de Recerca (VHIR) promovem la recerca biomèdica, la innovació i la docència. Més de 1.800 persones busquen comprendre les malalties avui per millorar-ne el tractament demà.
Recerca
Treballem per entendre les malalties, saber com funcionen i crear millors tractaments per als pacients. Coneix els nostres grups i les seves línies de recerca.
Persones
Les persones són el centre del Vall d'Hebron Institut de Recerca (VHIR). Per això ens vinculem amb els principis de llibertat de recerca, igualtat de gènere i actitud professional que promou l’HRS4R.
Assaigs clínics
La nostra tasca no és només bàsica o translacional; som líders en recerca clínica. Entra per saber quins assaigs clínics estem duent a terme i perquè som referent mundial en aquest camp.
Progrés
Volem que la recerca que es fa al Vall d’Hebron Institut de Recerca (VHIR) sigui un motor de transformació. Com? Identificant noves vies i solucions per fomentar la salut i el benestar de les persones.
Core facilities
Oferim un suport especialitzat als investigadors tant interns com externs, des d’un servei concret fins a l’elaboració d’un projecte complet. Tot, amb una perspectiva de qualitat i agilitat de resposta.
Actualitat
Et donem una porta d’entrada per estar al dia de tot el que passa al Vall d’Hebron Institut de Recerca (VHIR), des de les últimes notícies fins a les activitats i iniciatives solidàries futures que estem organitzant.
Speaker: Dr. Nicolás Fissolo, is senior investigator at the Centre d’Esclerosi Multiple de Catalunya (Cemcat) at the Vall d'Hebron University Hospital in Barcelona. He graduated with a degree in biological chemistry at the University of Córdoba, Argentina in 1999. In 2005, he obtained a Ph.D. in human biology from the University of Ulm, Germany for his work in the DNA vaccine field. Afterwards he carried out a 3-year postdoctoral stage at the Hertie Institute for Clinical Brain Research, in Tübingen, Germany focused in the study of antigen presentation in MS. In 2008, he joined the group of Xavier Montalban, at the Institut de Recerca, Hospital Vall d’Hebron in Barcelona where he is currently working.
Abstract: In the context of multiple sclerosis (MS), the need for objective and measurable indicators of the underlying pathological processes is critical to predict response, disease progression, prognosis and outcome of disease. Therefore, the search for biomarkers, is a continuously expanding field, and a large number of molecules have been explored so far; but only a few have been validated, and even fewer are currently used in clinical practice. In neurological disorders like MS, because of its close proximity to the target organ, the cerebrospinal fluid (CSF) will probably capture better the pathological changes taking place in the central nervous system of MS patients. However, due to the difficulties to access to longitudinal CSF samples to follow-up patient’s progression, it should investigate whether the CSF biomarker is also detected in peripheral blood, serum or plasma, and whether the differences observed in protein abundance in the CSF are also present in blood. In this presentation we will discuss the role of different biomarkers in patients with MS, and we will talk about the transition from CSF to blood guided by the evolution of technologies for biomarker detection.
Host: Dr. Manuel Comabella López, main researcher, group Clinical Neuroimmunology at Vall d’Hebron Research Institute (VHIR)
Register here to attend by Zoom: https://gencat.zoom.us/j/95396181541
